Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: A comparison between murine and rabbit antibodies
作者： Magali Svrcek , Jérôme Cros , Raphael Maréchal , Jean-Baptiste Bachet , Jean-François Fléjou
DOI: 10.1111/HIS.12577
关键词:
摘要: Aims: The human equilibrative nucleoside transporter 1 (hENT1) expression level in pancreatic ductal adenocarcinoma (PDAC) may predict survival gemcitabine-treated patients after resection. These results have been obtained with a murine anti-hENT1 antibody (10D7G2) that is not commercially available. Another antibody, which rabbit-derived (SP120), appears to no predictive value local, advanced or metastatic PDAC. We aimed study whether the two antibodies are equivalent. Methods and results: compared hENT1 both resected were correlated overall (OS) following gemcitabine treatment. Tissues from sets of (n = 147 each) stained SP120 by use different equipment, an amplification technique being used for set 2. rate 'hENT1 high' cases was lower (set 1, 7% versus 48%; 2, 11% 38%). With technique, high globally similar between antibodies. However, concordance found only 50% cases. High OS 10D7G2 (hazard ratio 0.49; 95% confidence interval 0.24-0.98; P 0.045). Conclusions: Further prospective studies seem be warranted before testing PDAC daily practise.
ulb.ac.be
sci-hub.se 参考文章(10)
James J. Farrell, Hany Elsaleh, Miguel Garcia, Raymond Lai, Ali Ammar, William F. Regine, Ross Abrams, A. Bowen Benson, John Macdonald, Carol E. Cass, Adam P. Dicker, John R. Mackey, Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer Gastroenterology. ,vol. 136, pp. 187- 195 ,(2009) , 10.1053/J.GASTRO.2008.09.067
Christina H. Wei, Tristan R. Gorgan, David A. Elashoff, O. Joe Hines, James J. Farrell, Timothy R. Donahue, A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers Pancreas. ,vol. 42, pp. 1303- 1310 ,(2013) , 10.1097/MPA.0B013E3182A23AE4
Raphaël Maréchal, Jean–Baptiste Bachet, John R Mackey, Cécile Dalban, Pieter Demetter, Kathryn Graham, Anne Couvelard, Magali Svrcek, Armelle Bardier–Dupas, Pascal Hammel, Alain Sauvanet, Christophe Louvet, François Paye, Philippe Rougier, Christophe Penna, Thierry André, Charles Dumontet, Carol E Cass, Lars Petter Jordheim, Eva–Laure Matera, Jean Closset, Isabelle Salmon, Jacques Devière, Jean–François Emile, Jean–Luc Van Laethem, None, Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma Gastroenterology. ,vol. 143, pp. 664- 674.e6 ,(2012) , 10.1053/J.GASTRO.2012.06.006
Steffen Ormanns, Volker Heinemann, Mitch Raponi, Jeff Isaacson, Rüdiger P. Laubender, Michael Haas, Stephan Kruger, Axel Kleespies, Elaina Mann, Mike Bartosiewicz, Thomas Kirchner, Stefan Boeck, Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody European Journal of Cancer. ,vol. 50, pp. 1891- 1899 ,(2014) , 10.1016/J.EJCA.2014.04.023
Gregory D. Leonard, Sen H. Zhuang, Jean L. Grem, Paul J. Ross, David Cunningham, Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer. Journal of Clinical Oncology. ,vol. 20, pp. 4124- 4126 ,(2002) , 10.1200/JCO.2002.99.125
Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Ihor Bondarenko, Irina Davidenko, Volodymyr Bondar, August Garin, Stefan Boeck, Steffen Ormanns, Volker Heinemann, Claudio Bassi, T.R. Jeffrey Evans, Roland Andersson, Hejin Hahn, Vince Picozzi, Adam Dicker, Elaina Mann, Cynthia Voong, Paramjit Kaur, Jeff Isaacson, Andrew Allen, Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity Journal of Clinical Oncology. ,vol. 31, pp. 4453- 4461 ,(2013) , 10.1200/JCO.2013.51.0826
William Greenhalf, Paula Ghaneh, John P Neoptolemos, Daniel H Palmer, Trevor F Cox, Richard F Lamb, Elizabeth Garner, Fiona Campbell, John R Mackey, Eithne Costello, Malcolm J Moore, Juan W Valle, Alexander C McDonald, Ross Carter, Niall C Tebbutt, David Goldstein, Jennifer Shannon, Christos Dervenis, Bengt Glimelius, Mark Deakin, Richard M Charnley, François Lacaine, Andrew G Scarfe, Mark R Middleton, Alan Anthoney, Christopher M Halloran, Julia Mayerle, Attila Oláh, Richard Jackson, Charlotte L Rawcliffe, Aldo Scarpa, Claudio Bassi, Markus W Büchler, European Study Group for Pancreatic Cancer, Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial Journal of the National Cancer Institute. ,vol. 106, pp. 1- 10 ,(2014) , 10.1093/JNCI/DJT347
Jennifer Spratlin, Randeep Sangha, Darryl Glubrecht, Laith Dabbagh, James D. Young, Charles Dumontet, Carol Cass, Raymond Lai, John R. Mackey, The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clinical Cancer Research. ,vol. 10, pp. 6956- 6961 ,(2004) , 10.1158/1078-0432.CCR-04-0224
K Eto, H Kawakami, M Kuwatani, T Kudo, Y Abe, S Kawahata, A Takasawa, M Fukuoka, Y Matsuno, M Asaka, N Sakamoto, Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer British Journal of Cancer. ,vol. 108, pp. 1488- 1494 ,(2013) , 10.1038/BJC.2013.108
Marianne Sinn, Bruno Valentin Sinn, Jens Stieler, Uwe Pelzer, Jana Kaethe Striefler, Helmut Oettle, Marcus Bahra, Bernd Dörken, Carsten Denkert, Hendrik Blaeker, Hanno Riess, Philipp Lohneis, Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial. Journal of Clinical Oncology. ,vol. 32, pp. 4124- 4124 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.4124